Pfizer's meningococcal vaccine candidate clears regulatory step

The FDA accepted Pfizer's biologics license application for its pentavalent meningococcal vaccine candidate intended for people between the ages of 10 and 25. 

The candidate is a combination of Pfizer's two licensed meningococcal vaccines, according to a Dec. 28 news release from Pfizer. If the product is approved, the meningococcal vaccine would be the first to change the two- to four-dose series into one jab.

Pfizer said it expects a final decision by October 2023. 

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars